Navigation Links
Drugs for hair loss and BPH may result in loss of libido, ED in men
Date:1/11/2011

(Boston) Researchers from Boston University School of Medicine (BUSM), in collaboration with colleagues at Lahey Clinic and from Denmark and Germany, have found that 5a-reductase inhibitors (5a-RIs), while improving urinary symptoms in patients with benign prostatic hyperplasia (BPH) and possible hair loss prevention, produces significant adverse effects in some individuals including loss of libido, erectile dysfunction (ED), ejaculatory dysfunction and potential depression. These findings, which currently appear on-line in Journal of Sexual Medicine, suggest that extreme caution should be exercised prior to prescribing 5a-RIs therapy to patients for hair growth or for BPH symptoms.

5a-RIs, finasteride (Propecia) and dutasteride, have been approved for treatment of lower urinary tract symptoms, due to BPH, with marked clinical efficacy. Finasteride is also approved for treatment of hair loss (androgenetic alopecia). Although the adverse side effects of these agents are thought to be minimal, the magnitude of adverse effects on sexual function, gynecomastia, depression, and quality of life remains ill-defined.

In order to determine the potential extent of this problem, the researchers examined the data reported in various clinical studies concerning the side effects of finasteride and dutasteride. After a review of the literature the researchers found that in a subset of men, prolonged adverse effects on sexual function such as erectile dysfunction and diminished libido were reported, raising the possibility of a causal relationship.

According to the researchers, the adverse side effects of 5a-RIs on sexual function, gynecomastia and the impact on the overall health have received minimal attention. However, in some patients, these side effects are persistent with regard to sexual function and with an emotional toll including decreased quality of life.

"The potential widespread use of 5a-RIs for treatment of BPH, prostate cancer and male pattern hair loss may produce undesirable adverse side effects on overall health and in particular, vascular health and sexual function in a subgroup of susceptible patients, " said lead author Abdulmaged M. Traish, MBA, PhD, a professor of biochemistry and professor of Urology at BUSM. "Furthermore, treatment of hair loss, a benign condition with 5a-RIs may produce persistent side effects in a number of young patients," he added.

"Honest and open discussion with patients to educate them on these serious issues must be pursued prior to commencing therapy because, in some patients, these adverse effects are persistent and may be prolonged and patients do not recover well after discontinuation from drug use," cautioned Traish.

The researchers believe additional clinical and preclinical studies are warranted to determine the reason for why some of these adverse effects persist in some individuals.


'/>"/>

Contact: Gina DiGravio
gina.digravio@bmc.org
617-638-8480
Boston University Medical Center
Source:Eurekalert

Related medicine news :

1. Evidence lacking for widespread use of costly antipsychotic drugs, says Stanford researcher
2. Studies Decipher How Anti-Smoking Drugs Work
3. Structure of key molecule in immune system provides clues for designing drugs
4. Heartburn Drugs May Raise Pneumonia Risk
5. Trio of drugs may combat triple negative breast cancer
6. Drugs are safe, active in patients normally ineligible for clinical trial
7. Certain Breast Cancer Drugs Linked With Heart Risks in Older Women
8. Economist honored for study on impact of new cancer drugs on life expectancy
9. FDA Panel Votes Against Drugs Said to Prevent Prostate Cancer
10. FDA Panel to Vote on Drugs Said to Prevent Prostate Cancer
11. FDA Panel to Vote on Drugs to Prevent Prostate Cancer
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... , ... February 10, 2016 , ... ... announces that his office is now offering a variety of comprehensive procedures for ... enhancement, eyebrow lift, facial volume restoration, lip enhancement and nasal reshaping. , ...
(Date:2/10/2016)... AZ (PRWEB) , ... February 10, 2016 , ... Ongoing ... the Aging Life Care Association™ (ALCA) to conduct a survey that takes a closer ... experts released today illustrates the prevalence and causes of TBI among the aging population, ...
(Date:2/10/2016)... ... February 10, 2016 , ... ... welcomes S.S. Nesbitt as the latest addition to its growing list of Partner ... locations throughout the Southeast, from Orlando to Huntsville and in between. , Harnessing ...
(Date:2/10/2016)... ... February 10, 2016 , ... AxoGen, Inc. (NASDAQ: AXGN), a leading ... the fourth quarter and full year ended December 31, 2015 on Monday, February 29, ... webcast for the investment community following the release at 4:30 PM ET. Investors interested ...
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... four time Emmy award winner and inspirational speaker Jan Fox will serve as ... by Speaking Boldly will provide participants with tools to more effectively communicate with ...
Breaking Medicine News(10 mins):
(Date:2/10/2016)... , February 10, 2016 A ... which will be held at Victoria Park Plaza in ... an informative seminar on technology and future advances for late ... led by Lorna Graham , associate director of project ... to keep up with new regulations and standards in late ...
(Date:2/10/2016)... Puerto Rico Healthcare and Life Sciences Report 2016 ... Report 2016 . --> Focus Reports releases ... Sciences Report 2016 . pharmaceuticals , or ... world for pharma manufacturing, a territory with significantly improved capabilities ... per square mile than anywhere else on the planet. ...
(Date:2/10/2016)... , Feb. 10, 2016 Convergence ... confluence of various technologies that results in ... unavailable. These opportunities create a cyclical system ... turn, drives the development of new technologies. ... characterized by technology convergences, which are constantly ...
Breaking Medicine Technology: